Memorial Sloan Kettering Cancer Center researchers have created a multimodal machine learning (ML) tool that can identify patients with metastatic breast cancer most likely to respond to CDK4/6 inhibitors based on clinicopathologic and genomic features. “There’s a huge need in clinic to identify patients who may or may not benefit…

New data from the OlympiA clinical trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) show that the PARP inhibitor olaparib (Lynparza) significantly improves survival in patients with high-risk, BRCA-positive, HER2-negative early breast cancer. The findings, after a median follow-up of 6.1 years, further support the drug’s use…

A study from Johns Hopkins University, published in Biophotonics Discovery, examined how skin tone affects the accuracy of photoacoustic imaging (PAI), a technology gaining traction in breast cancer diagnostics, especially in situations where traditional mammography is insufficient. The study shows how image reconstruction methods and laser wavelengths influence the visibility…

An investigational vaccine designed by researchers at the Washington University (WashU) School of Medicine to prevent tumor recurrence has shown promising results in a phase I trial among patients with triple-negative breast cancer (TNBC). The neoantigen DNA vaccine targets patient-specific cancer neoantigens—mutant proteins or amino acid sequences that arise from…

A group of Korean researchers has determined that women under 45 who get hormone-receptor negative breast cancer are at higher risk of distant recurrence even several years after treatment.  These researchers write, “Because young patients with hormone receptor–positive, ERBB2-negative breast cancer have a relatively long life expectancy, the cumulative risk…

A groundbreaking study from Harvard Medical School researchers should change long-held beliefs about the BRCA1 gene and its role in breast cancer. Researchers have discovered that even a single defective copy of the BRCA1 gene can make breast cells more susceptible to cancer, without the need for a second genetic…

Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a computational method to assess which patients with metastatic triple-negative breast cancer could benefit from immunotherapy. The work, published in the Proceedings of the National Academy of Sciences, aims to develop a more…

A new study from investigators from the Clínica Universidad de Navarra in Spain shows that approximately 40% of postmenopausal hormone receptor-positive breast cancer cases may be associated with excess body fat. This finding, published in the Journal of Epidemiology & Community Health, shows that the attributable effects of excess body…

Triple-negative breast cancer (TNBC), the most aggressive and difficult-to-treat form of breast cancer, may soon have a new treatment option. Researchers from the Brigham and Women’s Hospital, part of the Mass General Brigham healthcare system, have identified a promising therapeutic strategy that combines two types of drugs, setting the stage…

A recent study by researchers at the Baylor College of Medicine has shed light on the role of DAPK3 in triple-negative breast cancer (TNBC), detailing its regulation of epithelial-mesenchymal transition (EMT) which is a process linked to cancer metastasis. This research, published in the journal PNAS Nexus, provides a better…

A recent study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center has found that common treatments for breast cancer—chemotherapy, radiation, and surgery—may contribute to accelerated biological aging in survivors. The research, published in the Journal of the National Cancer Institute, demonstrates that markers of cellular aging such as…

Commercially available artificial intelligence (AI) algorithms that help radiologists immediately detect breast cancer at mammography screening can also highlight women who are at risk years before their eventual diagnosis, research indicates. The findings, reported in JAMA Network Open, could offer a pathway for personalized screening that may lead to the…

Owkin and AstraZeneca have partnered on an AI-powered tool to pre-screen for germline BRCA (gBRCA) in breast cancer, directly from digitized pathology slides. This tool aims to significantly accelerate and expand access to gBRCA testing that many patients may not be considered for. The solution is currently in development and…

Extended estrogen suppression in postmenopausal breast cancer does not increase patients’ risk of coronary artery calcification, as some prior studies had indicated, new evidence from an international collaboration shows. This finding helps address a key issue in treating this population  Aromatase inhibitors are a mainstay in treating hormone receptor-positive postmenopausal…

Researchers from the Mass General Brigham have revealed that Black women face a higher risk of dying from breast cancer than white women across all tumor subtypes. The meta-analysis, published in the Journal of Clinical Oncology, shows that Black women’s risk of death varies from 17% to 50% higher depending…